Loring Wolcott & Coolidge Fiduciary Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-32	Closed	-$3K	–	774
2021 Q2	$3K	Buy	+32	New	+$2.54K	﹤0.01%	780
2021 Q1	–	Sell	-18	Closed	-$2K	–	357
2020 Q4	$2K	Buy	+18	New	+$1.43K	﹤0.01%	739
2017 Q2	–	Sell	-1,100	Closed	-$97K	–	637
2017 Q1	$97K	Hold	1,100	–	–	﹤0.01%	352
2016 Q4	$91K	Hold	1,100	–	–	﹤0.01%	341
2016 Q3	$102K	Hold	1,100	–	–	﹤0.01%	330
2016 Q2	$86K	Hold	1,100	–	–	﹤0.01%	336
2016 Q1	$91K	Hold	1,100	–	–	﹤0.01%	322
2015 Q4	$115K	Hold	1,100	–	–	﹤0.01%	326
2015 Q3	$150K	Hold	1,100	–	–	﹤0.01%	307
2015 Q2	$150K	Hold	1,100	–	–	﹤0.01%	307
2015 Q1	$137K	Hold	1,100	–	–	﹤0.01%	330
2014 Q4	$99K	Hold	1,100	–	–	﹤0.01%	362
2014 Q3	$79K	Hold	1,100	–	–	﹤0.01%	365
2014 Q2	$68K	Hold	1,100	–	–	﹤0.01%	398
2014 Q1	$75K	Hold	1,100	–	–	﹤0.01%	371
2013 Q4	$77K	Buy	+1,100	New	+$74.7K	﹤0.01%	357

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's BMRN Position: Q3 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 32 shares — an estimated $3K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in BMRN in Q4 2013 and held it in 16 quarters. The position peaked at $150K in Q3 2015. 512 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 32 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $3K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 16 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's BioMarin Pharmaceuticals position peaked at $150K in Q3 2015.
512 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.